Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,591,099 papers from all fields of science
Search
Sign In
Create Free Account
1 ML certolizumab pegol 200 MG/ML Prefilled Syringe [Cimzia]
Known as:
CERTOLIZUMAB PEGOL 200 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Cimzia]
, Cimzia 200 MG in 1 ML Prefilled Syringe
, Cimzia 200 MG per 1 ML Prefilled Syringe
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Broader (1)
1 ML certolizumab pegol 200 MG/ML Prefilled Syringe
Cimzia
Prefilled Syringe
Sodium Acetate
Sodium Chloride
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis
Arnold Lee
,
L. Scott
BioDrugs
2020
Corpus ID: 214618946
Certolizumab pegol (Cimzia ® ) is a PEGylated, Fab′-only, recombinant humanized antibody against TNF-α. Subcutaneous certolizumab…
Expand
2018
2018
Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Leishmania Infection of Human Macrophages
K. Arens
,
Christodoulos Filippis
,
+6 authors
G. van Zandbergen
Front. Immunol.
2018
Corpus ID: 51873913
Tumor necrosis factor α (TNFα) drives the pathophysiology of human autoimmune diseases and consequently, neutralizing antibodies…
Expand
Review
2018
Review
2018
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
Heejin Lim
,
Sang Hyung Lee
,
+4 authors
Y. Heo
International journal of molecular sciences
2018
Corpus ID: 3798251
The binding of the tumor necrosis factor α (TNFα) to its cognate receptor initiates many immune and inflammatory processes. The…
Expand
Review
2017
Review
2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
M. Corbett
,
F. Chehadah
,
+8 authors
L. Bojke
Health technology assessment
2017
Corpus ID: 43665347
BACKGROUND Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic…
Expand
2017
2017
Certolizumab pegol administration devices: a profile of their use and usability
K. Lyseng-Williamson
2017
Corpus ID: 80316640
Certolizumab pegol (Cimzia®), a tumour necrosis factor-α (TNF) antagonist, is an effective and well-tolerated option for the…
Expand
Review
2016
Review
2016
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
P. Turecek
,
M. J. Bossard
,
Freddy Schoetens
,
I. Ivens
Journal of pharmaceutical sciences
2016
Corpus ID: 24533028
Review
2014
Review
2014
Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis
Sohita Dhillon
Drugs
2014
Corpus ID: 19083482
Certolizumab pegol (Cimzia®) is a polyethylene glycolylated antigen-binding fragment of a recombinant human monoclonal antibody…
Expand
2013
2013
Antibody fragments: Prolonging circulation half-life special issue-antibody research
A. Herrington-Symes
,
M. Farys
,
H. Khalili
,
S. Brocchini
2013
Corpus ID: 26226358
Antibodies are currently the fastest growing class of therapeutic proteins. When antibody fragments are included, there are over…
Expand
Review
2013
Review
2013
Certolizumab Pegol
Emma D. Deeks
Drugs
2013
Corpus ID: 21522812
Certolizumab pegol (Cimzia®) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal…
Expand
Review
2013
Review
2013
A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
S. Iannazzo
,
M. De Francesco
,
D. Gómez-Ulloa
,
M. Benucci
Expert review of pharmacoeconomics & outcomes…
2013
Corpus ID: 207190912
Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE